Condition: Hyperkalemia · Sponsor: Waterstone Pharmaceutical (Wuhan) Co., LTD.
This clinical trial consists of 2 parts, Part A and Part B. Part A consists of a 2-day randomized, double-blind, placebo-controlled corrective phase (CP) and a 28-day randomized, double-blind, placebo-controlled maintenance phase (MP). Part B (open-label extension, OLE) is an open-label, 11-month extension study carried out in participants who come from Part A and meet certain inclusion criteria.
This description comes directly from the study's public registry record.
Waterstone Medical Center · +86 27 87531661 · mpr2024_waterstone@waterstonepharma.com
Always discuss trial participation with your own doctor first.
| Investigator Site 02 | Bengbu, Anhui, China | Recruiting |
| Investigator Site 03 | Wuhu, Anhui, China | Recruiting |
| Investigator Site 48 | Chongqing, Chongqing Municipality, China | Recruiting |
| Investigator Site 04 | Xiamen, Fujian, China | Recruiting |
| Investigator Site 05 | Lanzhou, Gansu, China | Recruiting |
| Investigator Site 07 | Guangzhou, Guangdong, China | Recruiting |
| Investigator Site 06 | Zhanjiang, Guangdong, China | Recruiting |
| Investigator Site 08 | Huizhou, Guangxi, China | Recruiting |
| Investigator Site 09 | Nanning, Guangxi, China | Recruiting |
| Investigator Site 10 | Nanning, Guangxi, China | Recruiting |
| Investigator Site 11 | Guiyang, Guizhou, China | Recruiting |
| Investigator Site 12 | Haikou, Hainan, China | Recruiting |
+ 38 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07251309